These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2423791)

  • 1. Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients.
    Neumann G; Wilke G; Reimold WV; Pierce DM; Giesing M
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S20-4. PubMed ID: 2423791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing.
    Pierce DM; Warrington SJ; Franklin RA
    Biopharm Drug Dispos; 1988; 9(2):147-57. PubMed ID: 2897212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.
    Pierce DM; Abrams SM; Franklin RA
    Eur J Clin Pharmacol; 1987; 32(6):619-23. PubMed ID: 3653231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.
    Pierce DM; Abrams SM; Franklin RA
    Eur J Clin Pharmacol; 1988; 35(2):195-8. PubMed ID: 3191938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in the pharmacology and pharmacokinetics of indoramin.
    Archibald JL
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S16-9. PubMed ID: 2423790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of indoramin in man.
    Draffan GH; Lewis PJ; Firmin JL; Jordan TW; Dollery CT
    Br J Clin Pharmacol; 1976 Jun; 3(3):489-95. PubMed ID: 788751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.
    Norbury HM; Franklin RA; Marrott PK; Warrington SJ
    Eur J Clin Pharmacol; 1983; 25(2):243-6. PubMed ID: 6628508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin.
    Pierce DM
    Xenobiotica; 1990 Dec; 20(12):1357-67. PubMed ID: 1981634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
    Pierce DM; Smith SE; Franklin RA
    Eur J Clin Pharmacol; 1987; 33(1):59-65. PubMed ID: 3691597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oral indoramin.
    Volans GN; Jeffereys D; Latham AN; Frost T
    Curr Med Res Opin; 1982; 8(1):51-3. PubMed ID: 7105823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of oral indoramin during pregnancy.
    Schabort I; Odendaal HJ; Pierce DM
    Br J Clin Pharmacol; 1990 Apr; 29(4):397-401. PubMed ID: 2328193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.
    Norbury HM; Franklin RA; Marrott PK; Warrington SJ
    Eur J Clin Pharmacol; 1984; 27(2):247-9. PubMed ID: 6499905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between indoramin and ethanol.
    Abrams SM; Pierce DM; Johnston A; Hedges A; Franklin RA; Turner P
    Hum Toxicol; 1989 May; 8(3):237-41. PubMed ID: 2744781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemodynamic dose-response effects of intravenous indoramin in acute heart failure complicating myocardial infarction.
    Silke B; Nelson GI; Verma SP; Frais MA; Reynolds G; Jackson N; Taylor SH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S102-6. PubMed ID: 2423781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
    Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
    Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acute and chronic effects of indoramin on renal function, hemodynamics, and transport.
    Morrison G; Spar B; Walker BR; Goldfarb S
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S25-9. PubMed ID: 2423792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid chromatographic assay using electrochemical detection for the quantitation of indoramin in human plasma.
    Leelavathi DE; Soffer EF; Dressler DE; Knowles J
    J Pharm Sci; 1986 Apr; 75(4):421-3. PubMed ID: 3723366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.
    Hasselström J; Eriksson S; Persson A; Rane A; Svensson JO; Säwe J
    Br J Clin Pharmacol; 1990 Mar; 29(3):289-97. PubMed ID: 2310653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
    Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of nicorandil in humans: an overview.
    Frydman A
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S34-44. PubMed ID: 1282174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.